Aminopyrazine Compounds for Selective Itk Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tyrosine kinase inhibitors lack selectivity for Interleukin-2 inducible T-cell kinase (Itk) over Lck, which is crucial for effectively treating T-cell mediated diseases without affecting other kinases.
Innovation Solution
Development of novel pyridine or pyrazine compounds represented by formula (I), which are designed to selectively inhibit Itk, thereby preventing and treating Itk-related diseases such as allergic asthma, atopic dermatitis, and HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current tyrosine kinase inhibitors are used, then kinase inhibition activity is achieved, but selectivity for Itk over Lck is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the pyridine/pyrazine core structure. The R1, R2, R3, and R4 groups are strategically positioned to create localized interaction zones that differentiate Itk binding from Lck binding, achieving selectivity through localized structural modifications rather than global changes to the molecule.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types, positions, and electronic properties on the heterocyclic core. By adjusting parameters such as substituent electronegativity, steric bulk, and hydrogen bonding capability at specific positions, the invention optimizes both Itk selectivity and overall kinase inhibition profile.
2Adaptability or versatility
If broad-spectrum kinase inhibition is achieved, then multiple disease pathways are targeted, but specificity for Itk-mediated diseases is reduced
Solution Approach 1:
The patent applies segmentation by dividing the kinase inhibition function into distinct modular components: the heterocyclic core provides the primary Itk-binding interaction, while separately positioned substituents (R1-R4 groups) provide secondary interactions that can be independently optimized for either Itk specificity or broader kinase coverage depending on therapeutic needs.
3Reliability
If novel pyridine or pyrazine compounds with selective Itk inhibition are developed, then Itk-related diseases can be treated with minimal effects on other kinases, but drug development complexity increases
Solution Approach 1:
The patent applies universality by designing a versatile pyridine/pyrazine core structure that can serve multiple therapeutic indications for Itk-mediated diseases (allergic asthma, atopic dermatitis, HIV infection) while maintaining a consistent structural framework. This universal core with variable substituents allows one molecular scaffold to address multiple diseases without requiring complete redesign for each indication.
Data Source
AI summary
A compound of formula (I):wherein all symbols have the same meanings as defined in the specification; a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, has an Itk inhibitory activity, and is useful as a method for preventing and/or treating atopic dermatitis, and the like.